Last reviewed · How we verify
NCT06816537: SZTEDENT-laser
The Effect of Low-level Laser Therapy to Reduce Pain Caused by Orthodontic Separators: A Randomized, Double-blind Place-bo-controlled, Split-mouth Study
NA trial testing Low Level Laser Therapy in Orthodontic Pain in 33 participants. Completed in 23 December 2021.
23 December 2021
Quick facts
| Lead sponsor | Szeged University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 33 |
| Start date | 5 July 2021 |
| Primary completion | 23 December 2021 |
| Estimated completion | 23 December 2021 |
| Sites | 1 location across Hungary |
Drugs / interventions tested
- Low Level Laser Therapy — full drug profile →
- No Interventions — full drug profile →
Conditions studied
- Orthodontic Pain — all drugs for Orthodontic Pain →
Sponsor
Szeged University
Who can join
Adults 18 to 50, any sex, with Orthodontic Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Thirty-three (n=33) participants from the Department of Orthodontics and Pediatric Dentistry, University of Szeged will be randomly assigned into two groups. A randomly assigned, split-mouth design will be used to avoid inter-individual biologic variation between patients. First, it will be randomly determined whether the upper or lower jaw would be involved in the study; after choosing the jaw blindly, the actual dental arch in the mouth will further be divided vertically, into right and left halves (quadrants) in each patient. One half will be the experimental side (i.e. the test quadrant) and will receive laser therapy, while the other half will be the placebo side (i.e. placebo quadrant) which will receive no laser, only placebo therapy. In the experimental group, a low-level medical gallium-aluminum-arsenide (GaAlAs) diode laser device (wavelength 980 nm, power: 100mW, producing 6 J energy), with continuous wave will used on the 1st permanent molars in the test quadrants. Using the split mouth design, patients will receive only a single dose immediately after the placement of orthodontic separators. Specified points in each quadrant will be treated from mesial, central and distal directions on the mucosa both buccally and lingually/palatinally with 10-10 sec for each, altogether for 60 sec, producing 36 J energy per molar. During the placebo treatment session, a similar procedure to that of the laser treatment session will be carried out, but with no laser irradiation. Therefore, to control the patient's pain-related behavior, and to maintain the blinded protocol, the handpiece will also be held on the placebo treatment side without laser irradiation following a similar application protocol. Patients will be instructed to denote their pain sensation levels (which is expected to be the primary come measure of the study), according to the localization (upper/lower jaw; right/left side) and the given appointments following the treatments: at 0 hours (i.e. within 5 minutes of placing the elastic separators), at 6 hours , at 12 hrs , at 24 hrs , at 48 hrs and at 72 hrs ,after treatment (laser/placebo) in resting position of the mandible (spontaneous pain) and during mastication, on a Visual Analog Scale (VAS), ranging from 0 (no pain) to 100 (severe pain).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Effect of Low-Level Laser Therapy to Reduce Pain Caused by Orthodontic Separators: A Randomized, Double-Blind Placebo-Controlled, Split-Mouth Study.
Dezfully AK, Gajdács M, Pató AE, Kárpáti K, et al · · 2025 · PMID 40422601 · DOI 10.3390/dj13050181
Verify or expand the search:
- PubMed search for NCT06816537
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Low Level Laser Therapy
Trials testing the same drug.
- NCT07531654 — Comparative Effectiveness of Standard and Modified Laser Therapy in Myofascial Pain Management. · NA · not yet recruiting
- NCT07043868 — Effects and Feasibility of Photobiomodulation at 830nm Nanometers in the Treatment of Diabetic Ulcers · NA · not yet recruiting
- NCT07273591 — Effects of Low-level Laser Therapy on Spasticity and Gait Parameters in Chronic Stroke Patients With Spastic Plantar Fle · NA · recruiting
- NCT07128134 — Evaluation of the Effects of the Low-level Laser Therapy as an Adjunct to Nonsurgical Treatment in Patients With Periimp · NA · not yet recruiting
- NCT06759454 — Comparison of LASER Therapy and Desensitizing Agents in Dentinal Hypersensitivity · NA · not yet recruiting
Other Szeged University trials
Trials by the same sponsor.
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
- NCT07250945 — AdvaTx Laser Treatment for Vascular Birthmarks · NA · recruiting
- NCT07523022 — Comparison of the Effect of Gonadotropin and Clomiphene Citrate Treatment on Sperm Parameters and the Outcome of Assiste · Phase 4 · enrolling by invitation
- NCT06933407 — Elastographic Assessment of Suburethral Tissue in Continent and Incontinent Women · recruiting
- NCT04966416 — Calcinosis Reduction by Pyrophosphate in SSC · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06816537 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Szeged University
- Last refreshed: 13 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06816537.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing